<DOC>
	<DOCNO>NCT00485550</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability atomoxetine alone versus atomoxetine plus low-dose , sustained-release MPH child treatment-resistant ADHD .</brief_summary>
	<brief_title>Comparison Atomoxetine Plus Either Comparator Placebo Children With ADHD Who Have n't Responded Stimulant Therapy</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<mesh_term>Central Nervous System Stimulants</mesh_term>
	<criteria>Patients least 6 year age 12 year age visit 1 Patients must meet DSMIV diagnostic criterion ADHD Patients must retrospectively identify stimulant nonresponders Patients must normal intelligence assess investigator ( , without general impairment intelligence likely , investigator 's judgment , achieve score great equal 70 IQ test ) Patients must able swallow capsule Patients weigh less 22 kg 60 kg study entry Patients history Bipolar I Bipolar II Disorder , psychosis , pervasive developmental disorder Patients meet DSMIV criterion anxiety disorder autism Patients history seizure disorder and/or Rolandic seizures ( febrile seizure ) prior electroencephalogram ( ECG ) abnormalities absence seizure , patient take ( currently take ) anticonvulsant seizure control Patients history severe allergies one class medication multiple adverse drug reaction , include hypersensitivity MPH</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>